<DOC>
	<DOCNO>NCT00068952</DOCNO>
	<brief_summary>The purpose clinical trial study Edotecarin patient brain tumor glioblastoma multiforme ( GBM ) progression first recurrence follow initial treatment surgery , radiation chemotherapy .</brief_summary>
	<brief_title>Study IV Edotecarin Vs Temozolomide Carmustine ( BCNU ) Lomustine ( CCNU ) Patients With Glioblastoma Multiforme</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Lomustine</mesh_term>
	<criteria>Must biopsyproven GBM . First relapse ( progression recurrence ) GBM surgery ( biopsy ) treatment radiotherapy ( conventional fractionate external beam ) chemotherapy ( temozolomide nitrosureabased therapy ) Must past biopsy sample available central pathology review Must evidence GdMRI progressive/recurrent disease Must measurable disease GdMRI obtain within 14 day prior start study treatment Must least 18 year age Must Karnofsky Performance Status score least 70 If treat steroid , steroid dose must stable decrease 1 week prior randomization If treat anticonvulsant , must change type anticonvulsant 2 week prior randomization All acute toxic effect ( except alopecia ) prior treatment must resolve great grade 1 ( NCI Common Toxicity Criteria , Version 2.0 ) Baseline laboratory data must within follow limit : absolute neutrophil count least 1500 ; platelet least 100,000 ; hemoglobin least 9.0 g/dL ; serum creatinine great 1.5 mg/dL , total serum bilirubin great 1.5 time upper limit normal range ; SGOT SGPT great 2.5 time upper limit normal range ; albumin least 3.0 g/dL , serum urine pregnancy test ( female childbearing potential ) negative within 7 day prior start study treatment At least 6 week must elapse since completion prior nitrosurea therapy ; least 4 week since completion prior temozolomide therapy Must write informed consent Must able willing comply study procedure &amp; # 9 ; Must receive prior treatment radiotherapy ( conventional fractionate external beam ) ( neo ) adjuvant/concurrent chemotherapy ( temozolomide nitrosureabased containing ) regimen GBM Must receive prior treatment ( except surgical debulking ) first relapse ( progression recurrence ) GBM Must receive prior treatment another topoisomeraseI inhibitor ( e.g . irinotecan , topotecan , rubitecan ) Must radiosurgery radiotherapy within 1 month prior randomization Must prior brachytherapy chemotherapy wafer implantation Must prior highdose chemotherapy bone marrow stem cell support Must receive concomitant treatment investigational agent anticancer treatment study Must currently enrol another therapeutic clinical trial treatment GBM Must currently ( past 5 year ) malignancy ( except adequately treat basal cell squamous cell skin cancer noninvasive cervical cancer ) Must follow past 6 month : myocardial infarction ( heart attack ) , severe/unstable angina , coronary artery bypass graft , symptomatic congestive heart failure , cerebrovascular accident ( stroke ) , transient ischemic attack ( TIA ) Must follow past 2 month : pulmonary embolus ( blood clot lung ) , deep venous thrombosis ( blood clot vein ) , significant thromboembolic event Must ongoing cardiac dysrhythmia ( abnormal heart rhythm ) grade 2 high ( NCI Common Toxicity Criteria , Version 2.0 ) Must know human immunodeficiency virus ( HIV ) infection Must pregnant breastfeeding . Patients ( male female ) must surgically sterile ( postmenopausal female ) must agree use effective contraception period study treatment Must inappropriate entry study , judgment investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>